Basics Jazz Pharmaceuticals plc Jazz Pharmaceuticals PLC is a biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. IPO Date: June 1, 2007 Sector: Healthcare Industry: Biotech Market Cap: $6.75B Activated in VL: True Average Daily Range Avg Daily Range: $1.41 | 2.00% Avg Daily Range (30 D): $2.01 | 1.87% Avg Daily Range (90 D): $2.05 | 1.74% Institutional Daily Volume Avg Daily Volume: .58M Avg Daily Volume (30 D): 1.03M Avg Daily Volume (90 D): .96M Trade Size Avg Trade Size (Sh.): 84 Avg Trade Size (Sh.) (30 D): 51 Avg Trade Size (Sh.) (90 D): 49 Institutional Trades Total Inst.Trades: 9,604 Avg Inst. Trade: $4.53M Avg Inst. Trade (30 D): $6.36M Avg Inst. Trade (90 D): $6.25M Avg Inst. Trade Volume: .04M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $7.69M Avg Closing Trade (30 D): $15.75M Avg Closing Trade (90 D): $18.14M Avg Closing Volume: 59.42K         News May 30, 2025 @ 10:00 AM Zymeworks Announces NMPA Approval of Zanidatamab i... Source: N/A Apr 17, 2025 @ 10:00 AM Zymeworks to Report First Quarter 2025 Financial R... Source: N/A Mar 21, 2025 @ 10:00 AM Chimerix Reports Fourth Quarter and Year End 2024 ... Source: N/A Nov 21, 2024 @ 11:00 AM FDA Grants U.S. Approval of Ziihera® (zanidatam... Source: Zymeworks Inc. Oct 29, 2024 @ 10:00 AM Zymeworks Announces Participation in Upcoming Inve... Source: N/A Financials   TTM Q1 2025 Q4 2024 Basic EPS $7.79 $-1.52 $3.13 Diluted EPS $7.41 $-1.52 $3.02 Revenue $ 4.06B $ 897.84M $ 1.09B Gross Profit $ $ $ Net Income / Loss $ 482.2M $ -92.54M $ 191.12M Operating Income / Loss $ 594.53M $ -55.89M $ 190.77M Cost of Revenue $ $ $ Net Cash Flow $ 418.56M $ -550.92M $ 194.73M PE Ratio 14.70